Deutsche Bank Defends Arrowhead Amid ~16% Decline, Reiterates Buy
Shares of Arrowhead Research (NASDAQ: ARWR) were clobbered Monday as investors were disappointed with details of the company's dosing commencement in the Phase 2a trial of ARC-520. Shares plunged more than 16 percent to close at $17.37.
Deutsche Bank analyst Alethia Young had some reassuring comments for Arrowhead investors in a mid-day research note.
She attributed the downside in Arrowhead to "weakness in overall biotech sentiment" and suggested the company "remains the leader on timelines." She sees Arrowhead as "about a year ahead" for the company's HBV study.
Young set a fair value estimate for Arrowhead shares within $35 to $45 amid the Phase 2a data.
The Deutsche Bank analyst reiterated a Buy rating and $45 price target on shares of Arrowhead Research.
Latest Ratings for ARWR
|Aug 2016||Cantor Fitzgerald||Initiates Coverage on||Buy|
|May 2016||Chardan Capital||Initiates Coverage on||Buy|
|Sep 2015||Piper Jaffray||Maintains||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.